Search

Editors

Richard L. Cassin Publisher and Editor

Julie DiMauro Executive Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Elizabeth K. Spahn Contributing Editor

Eric Carlson Contributing Editor

Michael Kuria Contributing Editor

Thomas Fox Contributing Editor

Philip Fitzgerald Contributing Editor

Marc Alain Bohn Contributing Editor

Michael Scher Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Connect

Subscribe to receive the free FCPA Blog Daily

Close
« China Corruption Blotter (March 14, 2013) | Main | EU cracks down on timber trade »
Thursday
Mar142013

Docs collect billions for drug promos

ProPublica ran an exposé this week about big bucks for doctors who promote products for drug companies.

A Nashville psychiatrist led the pack, earning more than $1 million during the past four years for promotional talks and consulting for seven drug companies.

The investigative report by ProPublica's Tracy Weber and Charles Ornstein said 15 drug makers paid more than $2 billion to hundreds of thousand of physicians for promotional speaking, research, consulting, travel, meals, and related expenses since 2009.

The story named 22 doctors who made more than $500,000 since 2009 giving talks and consulting for drugmakers.

A couple of years ago in a post called the Novartis speakers bureau, we talked about those payments. If doctors at government owned or managed hospitals overseas are involved, we said, there could be FCPA violations.

Pfizer and a subsidiary paid $60 million last year to resolve FCPA offenses. Among other things, it paid doctors from European hospitals illegal travel and accommodation expenses.

And late last year, Eli Lilly paid $29 million to settle FCPA civil charges brought by the SEC involving payments to government-employed doctors overseas.

Other pharmas known to be facing FCPA investigations include AstraZeneca, Baxter International, Bio-Rad Laboratories, Bristol-Meyers Squibb, Covidien, GlaxoSmithKline, Merck, Sciclone Pharmaceuticals, and Teva.

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
All HTML will be escaped. Hyperlinks will be created for URLs automatically.